Advertisement
Screener

Tyra Biosciences, Inc. (TYRA) Overview

Tyra Biosciences, Inc. (TYRA) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -0.69; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.64; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -0.50; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -0.47; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$13.57$16.97$21.24$26.57$33.24$41.592025-11-062026-11-06$5.00$7.63$11.66$17.82$27.22$41.592021-11-082026-11-06$5.00$7.63$11.66$17.82$27.22$41.592021-09-152026-11-06$5.00$7.63$11.66$17.82$27.22$41.592021-09-152026-11-06$5.00$7.63$11.66$17.82$27.22$41.592021-09-152026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$21.14
Previous close
$21.98
Change
-$0.84
Change (%)
-3.80%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

TYRA
-16.28%
S&P 500
(m)

1 year

TYRA
+65.48%
S&P 500
(m)

3 years

TYRA
+59.84%
S&P 500
(m)

5 years

TYRA
+30.16%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual -0.69

-0.77-0.65-0.53-0.41-0.2931 Mar 2025: estimate (m); actual -0.4731 Mar 2025(m)30 Jun 2025: estimate (m); actual -0.4730 Jun 2025(m)30 Sept 2025: estimate (m); actual -0.5030 Sept 2025(m)31 Mar 2026: estimate (m); actual -0.6431 Mar 2026(m)30 Jun 2026: estimate (m); actual -0.6930 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)-0.69(m)(m)
1 Jan 202631 Mar 2026(m)-0.64(m)(m)
1 Jul 202530 Sept 2025(m)-0.50(m)(m)
1 Apr 202530 Jun 2025(m)-0.47(m)(m)
1 Jan 202531 Mar 2025(m)-0.47(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual -2.01

-2.09-1.85-1.61-1.38-1.1431 Dec 2021: estimate (m); actual -1.9131 Dec 2021(m)31 Dec 2022: estimate (m); actual -1.3231 Dec 2022(m)31 Dec 2023: estimate (m); actual -1.6231 Dec 2023(m)31 Dec 2024: estimate (m); actual -1.5131 Dec 2024(m)31 Dec 2025: estimate (m); actual -2.0131 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)-2.01(m)(m)
1 Jan 202431 Dec 2024(m)-1.51(m)(m)
1 Jan 202331 Dec 2023(m)-1.62(m)(m)
1 Jan 202231 Dec 2022(m)-1.32(m)(m)
1 Jan 202131 Dec 2021(m)-1.91(m)(m)

Revenue vs. Earnings

USD

No complete retained periods.

No complete retained periods.

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$21.14(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$21.14High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning TYRA

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending (m).

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
(m)
Profit margin
(m)
Return on assets · 12 month
(m)
Stock compensation expense · all employees · 12 months
(m)
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
(m)
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
1.44M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-14.03%*
Total return · month
-12.10%*
Total return · quarter
-31.46%*
Total return · half year
-39.35%*
Total return · year to date
-16.28%*
Total return · 1 year
65.48%*
Total return · 3 years
59.84%*
Total return · 5 years
30.16%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
(m)
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

Tyra Biosciences, Inc. Overview

View more →

(m)

(m)

SEC CIK
1863127
Industry (SIC)
2834 Pharmaceutical Preparations
Country of operation
United States
Business address
2656 STATE STREET, CARLSBAD, California, 92008, United States
Fiscal year end
1231
Phone
(619) 728-4760

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kardigan, Inc. (KARD)United States$1.346B
Bicara Therapeutics Inc. (BCAX)United States$1.309B-10.55
Oric Pharmaceuticals, Inc. (ORIC)United States$1.367B-8.00
First Tracks Biotherapeutics, Inc. (TRAX)United States$1.280B
Avalyn Pharma Inc. (AVLN)United States$1.267B
Damora Therapeutics, Inc. (DMRA)$1.250B-6.10
HARROW, INC. (HROW)United States$1.240B-42.77
OPKO HEALTH, INC. (OPK)United States$1.220B-15.59
LB PHARMACEUTICALS INC (LBRX)United States$1.220B-10.87
OMEROS CORP (OMER)United States$1.456B5.50